|
June 3, 2008
BioReliance Corporation announced today that Tomoko Kotani
has been named Representative Director, BioReliance KK, the company’s
new commercial office in Tokyo. Ms. Kotani will be responsible for
commercial operations in Japan.
Click
here to read the press release
May 7, 2008
BioReliance Corporation announced today that Donna Klein
has been named Vice President, Human Resources, responsible for
the human resource functions for all the company’s locations
including the United States, United Kingdom and Asia.
Click here to read the press release
April 22, 2008
BioReliance Corporation announced today that John L. Kolman,
PhD, has been named Senior Director, Research and Development.
Click here to
read the press release
April 10, 2008
BioReliance Corporation announces that registration is now
open for its 2008 Technical Seminar, “Current Concepts in
Biologics Safety Testing.” The one-day seminar will be offered
in
Copenhagen, Denmark, on May 28.
Click here to read
the press release
April 8, 2008
BioReliance Corporation announced today Darryl L. Goss has
been appointed Vice President, Toxicology/Laboratory Animal Diagnostic
Services (LADS), a new executive position created to lead this newly
formed Business Unit.
Click here to read the
press release
March 25, 2008
BioReliance Corporation has established a commercial office
in Tokyo, expanding its operations to significantly address the
growth opportunities in the Asia Pacific markets.
Click here
for more details in English.
Click here for more details
in Japanese.
February 28,
2008
BioReliance Offers 2008 Training Program: Guidelines for
Successful Biologics Safety Testing
The seminar will be offered in two locations: La Jolla, CA on April
3rd, and in Rockville, MD on May 8th. There is no fee for attendance,
and complimentary breakfast and lunch will be served. Topics will
include: Biologics Testing, Clearance Services and Cleaning Strategies;
Regulatory Trends and Validation Requirements; and Selecting a Contract
Testing Organization.
Click
here to read the press release.
February 28,
2008
BioReliance to Host 22nd Annual Genetic and Molecular Toxicology
Workshop
The workshop is scheduled for April 17-18, 2008, at the Gaithersburg
Marriott Hotel, Gaithersburg, MD. Topics include: regulatory aspects
of genetic toxicology; genetic toxicology test batteries, the theoretical
basis for each test system; protocol design, assay limitations,
dealing with positive results; interpretation of data; case studies;
and, the use of predictive screening assays. A tour of the genetic
toxicology laboratory is included.
Click
here to read the press release.
February 7, 2008
David L. Bellitt joins Bioreliance
David L. Bellitt has been named Vice President of Global Commercial
Operations, Biologics. Mr. Bellitt will be responsible for all global
commercialization activities, including sales, marketing and customer
service. He will also serve as a member of the Corporate Operating
Committee.
Click here to read
the press release.
January 8, 2008
James Kramer joins Bioreliance
James J. Kramer, Ph.D, joins BioReliance as Vice President of
Operations, U.S. Biologics. In his new position, Dr. Kramer is the US
Biologic Services Value Stream leader for the company and has direct
ownership for Program Management, Quality, GMP-Cell Banking, Clearance
Services, Molecular Biology, Cell Biology Microbiology, Virology,
In-Vivo Studies, Support Services and Facilities.
Click here to read the press release.
December 3, 2007
David A. Dodd to Lead BioReliance Corporation
David A. Dodd has joined BioReliance as the Company's President, Chief
Executive Officer and Chairman of the Board, effective December 3, 2007.
From 2000 through 2006, Mr. Dodd served as President and CEO of
Serologicals Corporation, a publicly traded company that was sold to
Millipore Corporation in 2006 for $1.4 billion. Prior to that, from 1995
Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc.
Click here to read the press release.
October 29, 2007
BioReliance Appoints Executive Chairman to be Interim CEO
and Announces Recent Senior Executive Additions
BioReliance Corporation has appointed its Executive Chairman, Charles
C. Harwood, Jr., to the additional post of Interim CEO, following
the announced resignation of Tim Derrington from the CEO position.
In addition, BioReliance announced that three senior executives
have joined the company since June: David E. Onions, Ph.D., as Chief
Scientific Officer, David S. Walker as Chief Financial Officer,
and Darryl L. Goss as Vice President of Global Process Excellence.
Click here to read
the press release.
October 10th,
2007
BioReliance Launches Next-Generation Genotoxicity Screening
Service
BioReliance has contracted with Gentronix to offer their GreenScreen
HC in vitro assay as a major part of BioReliance's portfolio
of genotoxicity screening services. GreenScreen HC, in conjunction
with Ames II assays, allows pharmaceutical companies to test for
genotoxic potential earlier in the preclinical development process,
using only a few milligrams of test compound as opposed to the gram
quantities required by current ICH regulatory tests.
Click here to read the
press release.
September 18th,
2007
BioReliance Corporation Launches iNet™ for Online
Results Tracking of Biological Safety Tests BioReliance is pleased
to announce the release of iNet, a proprietary information technology
system for submitting and tracking test article details via a controlled
and secure Internet access from any location worldwide. Now you
can view the status of current and past studies, keep informed of
when testing will be completed, download reports, and allow your
colleagues to view the status of your tests. Click here to read
the press release.
Click here to read the press
release.
April 30, 2007
David Onions, Ph. D., appointed Chief Scientific Officer
of BioReliance Corporation
Click
here to go to the article (PDF
version)
April 12, 2007
Avista Capital Partners acquires BioReliance Corporation
for approximately $210 million
Click
here to go to the article (PDF
version)
February 13, 2007
Avista Capital Partners announces intent to acquire BioReliance
Corporation from Invitrogen Corporation
Click
here to go to the article (PDF
version)
|  |
